Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL
Determinants of the Response to BTK Degraders (BTKd) in Double Refractory Chronic Lymphocytic Leukemia (CLL)
Nantes University Hospital
60 participants
Oct 9, 2025
OBSERVATIONAL
Conditions
Summary
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia (CLL), to facilitate access for the National Institute of Health and Medical Research (INSERM) to patients with double-refractory CLL. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent. These samples will first be sent to the Filothèque for temporary storage, and will then be transferred to CRCI²NA (Nantes - Angers Cancer and Immunology Research Center) for analysis with the aim of studying the mechanisms of resistance and response to BTK degraders (BTKd).
Eligibility
Inclusion Criteria5
- Patient with confirmed double refractory CLL to both BTKi and BCL-2i, defined as:
- Any patient who has received both a BTKi and a BCL-2i, regardless of treatment regimen, and has shown clinical progression either during treatment with both BTKi and BCL-2i, or within 36 months after stopping BCL-2i.
- Any patient identified with known biological resistance mutations to BTKi or BCL-2i, regardless of clinical progression.
- Patient who has provided informed consent to participate in the study.
- Patient covered by a social security health insurance plan
Exclusion Criteria3
- Minor patients.
- Adults under guardianship.
- Protected persons.
Interventions
This study is observational. Biological samples are collected as part of standard care or for research purposes and analyzed to characterize resistance mechanisms. No treatment or intervention is administered as part of the study protocol.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07099443